CHWY vs PETS vs WOOF vs BARK vs FRPT

For growth investors, Freshpet, Inc.

(FRPT) is the stronger pick with 13. 0% revenue growth year-over-year, versus -17. 2% for PetMed Express, Inc. (PETS). Freshpet, Inc. (FRPT) offers the better valuation at 21. 2x trailing P/E (41. 1x forward), making it the more compelling value choice. Analysts rate Chewy, Inc. (CHWY) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Freshpet, Inc.

(FRPT) is the cheapest at 21. 2x versus Petco Health and Wellness Company, Inc. at 86. 8x. On forward P/E, Petco Health and Wellness Company, Inc. is actually cheaper at 18. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Chewy, Inc.

(CHWY) delivered a total return of -66. 7%, compared to -95. 3% for BARK, Inc. (BARK). Over 10 years, the gap is even starker: FRPT returned +517. 3% versus BARK's -96. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Chewy, Inc.

(CHWY) is the lower-risk stock at 0. 70β versus BARK, Inc. 's 1. 96β — meaning BARK is approximately 178% more volatile than CHWY relative to the S&P 500. On balance sheet safety, PetMed Express, Inc. (PETS) carries a lower debt/equity ratio of 1% versus 192% for Chewy, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Freshpet, Inc.

(FRPT) is pulling ahead at 13. 0% versus -17. 2% for PetMed Express, Inc. (PETS). On earnings-per-share growth, the picture is similar: Chewy, Inc. grew EPS 893. 4% year-over-year, compared to 9. 5% for BARK, Inc.. Over a 3-year CAGR, FRPT leads at 22. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Freshpet, Inc.

(FRPT) is the more profitable company, earning 12. 6% net margin versus -6. 8% for BARK, Inc. — meaning it keeps 12. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FRPT leads at 8. 6% versus -7. 3% for BARK. At the gross margin level — before operating expenses — BARK leads at 62. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Petco Health and Wellness Company, Inc.

(WOOF) trades at 18. 8x forward P/E versus 41. 1x for Freshpet, Inc. — 22. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BARK: 220. 9% to $30. 00.

In this comparison, PETS (0.

4% yield) pays a dividend. CHWY, WOOF, BARK, FRPT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Freshpet, Inc.

(FRPT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 91), +517. 3% 10Y return). BARK, Inc. (BARK) carries a higher beta of 1. 96 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FRPT: +517. 3%, BARK: -96. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CHWY (Consumer Cyclical) and PETS (Healthcare) and WOOF (Consumer Cyclical) and BARK (Consumer Cyclical) and FRPT (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.